Smart Inhalers Market

• The Smart Inhalers Market Size is expected to strengthen as disease awareness increases and more effective interventions are developed.
• The leading Smart Inhalers Companies such as Teva Pharmaceutical, AstraZeneca, GlaxoSmithKline plc, AptarGroup, Inc, Novartis AG, OPKO Health, Inc, BreatheSuite Inc, adherium, Propeller Health, H&T Presspart Manufacturing Ltd, Zeolr Technologies Pvt Ltd , Findair Sp. z o. o, Lupin, Personal Air Quality Systems Pvt Ltd (PAQS), Biocorp, Cognita Labs, and others.

Request for Unlocking the Sample Pages of the “Smart Inhalers Market” 

Smart Inhalers Market By Product Type (Dry Powder Inhaler (DPI), Metered-Dose Inhaler, Device Type (Built In Smart Inhaler, Attach Type Smart Inhaler), Indication (Asthma, Chronic Obstructive Pulmonary Disorders [COPD], and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to advance at a respectable CAGR forecast till 2032 owing to the increasing cases of respiratory disorders and rise in pollution levels worldwide.

The Smart Inhalers Market was valued at USD XX billion in 2024, growing at a CAGR of 21.26% during the forecast period from 2025 to 2032 to reach USD XX billion by 2032. The smart inhalers Market is expanding rapidly due to the rising prevalence of respiratory conditions such as asthma & COPD, coupled with advancements in technology, growing smartphone adoption, and the increasing awareness of smart health solutions, which is expected to drive substantial demand for smart inhalers from 2025 to 2032.

According to data provided by the World Health Organization (WHO) (2024), in 2019 there were 262 million people affected by asthma. As per the same source in 2023, 392 million people were living with COPD with three-quarters of them living in low and middle-income countries. Smart inhalers enhance the management of respiratory conditions like asthma and COPD through advanced technological integration. Smart inhalers are equipped with sensors and connectivity features that enable real-time monitoring of medication usage and symptom tracking. They provide patients with adherence reminders and detailed usage analytics, facilitating more precise and personalized treatment regimens.

The rising global urbanization led to a steady increase in respiratory illness owing to increasing pollution, and a rise in the adoption of sedentary lifestyles such as smoking, which also leads to second-hand inhalation, which may also contribute to the Smart Inhalers Market Growth. The WHO in 2022 stated that in 2019, 99% of the global population resided in areas where air quality did not meet the WHO's guidelines. Smart inhalers are instrumental in managing respiratory conditions by enabling real-time monitoring and delivering personalized feedback, thereby improving adherence to treatment protocols. Their integration with digital health platforms addresses challenges from adverse air quality and lifestyle factors, optimizing respiratory health management.

The Smart Inhalers Market is anticipated to be driven by the rising smartphone adoption in both developed and developing nations, the affordability of smart health technology for patients & providers, and the rising demand for patient-centered care and integrated healthcare systems. Kepios stated that 4.27 billion people used the internet worldwide in April 2021, making up more than 60% of the world's population. It is anticipated that this number is expected to increase, so will public awareness of smart health tracking in the upcoming years.

Therefore, all the factors stated above collectively will drive the overall smart inhaler Market during the forecast period from 2025 to 2032. However, cybersecurity & privacy concerns, among others, may limit their end-user base, thus acting as key constraints limiting the Smart Inhalers Market Growth.

Smart Inhalers Market Segment Analysis

Smart Inhalers Market By Product Type (Dry Powder Inhaler (DPI), Metered-Dose Inhaler (MDI), Device Type (Built-In Smart Inhaler, Attach Type Smart Inhaler), Indication (Asthma, COPD, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World). In the product type segment of smart inhalers, the MDI category is expected to have a significant revenue share in the year 2024. The rapid growth of this product category can be attributed to the various features and applications of the MDI category. MDIs are equipped with integrated sensors that track medication usage and monitor inhalation techniques, ensuring accurate and consistent delivery of medication. They often include real-time feedback mechanisms that alert users if they are not using the device correctly, thereby improving adherence to prescribed treatments.

Additionally, smart MDIs connect to mobile apps or digital health platforms, providing users with detailed insights into their medication patterns, symptom progression, and environmental triggers. This data can be shared with healthcare providers to facilitate personalized treatment adjustments and better disease management. Enhanced features such as dose reminders, usage tracking, and connectivity with other health devices further support comprehensive respiratory care and contribute to improved patient outcomes.

Therefore, owing to the above-mentioned factors, the demand for the MDI category is expected to surge, thereby the category is expected to witness considerable growth, eventually contributing to the overall growth of the smart inhaler Market during the forecast period from 2025 to 2032.

North America is expected to dominate the overall Smart Inhalers Market

Among all the regions, North America is expected to dominate the Smart Inhalers Market in the year 2023 and is expected to do the same during the forecast period from 2025 to 2032. This is driven by the increasing prevalence of chronic respiratory diseases and the need for improved management tools. Advances in smart inhaler technology, regulatory support, and the introduction of innovative devices by key Market players are anticipated to significantly propel Market growth for smart inhalers from 2025 to 2032.

According to data from the Centers for Disease Control and Prevention (CDC) (2023), in 2021, approximately 11.5% of U.S. adults aged 18 years or older were current cigarette smokers, equating to an estimated 28.3 million individuals. As per the same source, over 16 million Americans are affected by smoking-related diseases. Smoking is a major risk factor associated with the development of COPD disorder among the population.

According to the American Lung Association data updated in April 2024, it stated that more than 34 million people are currently living in the US with chronic lung diseases like asthma and COPD. In addition to this, the same source stated that in 2023, approximately 11.7 million people in the US were living with chronic respiratory disorders, which over time makes it harder for patients to breathe. Furthermore, as per the data provided by the CDC (2023), in 2021, around 14.2 million people in the US had COPD.

Smart inhaler devices enhance treatment adherence by providing real-time tracking of medication use and delivering reminders, which can improve patient outcomes and control symptoms more effectively. Smart inhalers offer valuable data insights, helping healthcare providers tailor treatments and track disease progression. This plays a crucial role in managing the challenges associated with chronic lung diseases and supports better respiratory health management. Rising product development activities by regulatory bodies in the region will further boost the Market for smart inhalers.

• For example, in June 2023, Huma received U.S. Food and Drug Administration (FDA) Class II clearance for its disease-agnostic Software as a Medical Device (SaMD) platform. The platform's device-agnostic nature enables it to integrate with external third-party devices, such as heart rate and blood sugar monitors, as well as smart inhalers, thereby expanding its functionality and versatility.
• Additionally, in October 2021, Breathe Suite announced 510(k) clearance from the FDA for its Metered-Dose Inhaler V1 device. This new device converts standard inhalers into smart inhalers, designed to assist individuals with asthma and COPD. Therefore, the interplay of all the aforementioned factors above would provide a conducive growth environment for the North America region in the smart inhalers Market.

Smart Inhalers Companies In The Market Landscape

The leading Smart Inhalers Companies such as Teva Pharmaceutical, AstraZeneca, GlaxoSmithKline plc, AptarGroup, Inc, Novartis AG, OPKO Health, Inc, BreatheSuite Inc, adherium, Propeller Health, H&T Presspart Manufacturing Ltd, Zeolr Technologies Pvt Ltd , Findair Sp. z o. o, Lupin, Personal Air Quality Systems Pvt Ltd (PAQS), Biocorp, Cognita Labs, and others.

Recent Developmental Activities in the Smart Inhalers Market:

• In May 2024, Leicester initiated an NHS-funded trial to evaluate smart inhalers for children. As part of this study, approximately 300 children and young people in the area will be equipped with these advanced inhalers. The smart inhalers are designed to track medication usage and offer feedback through a dedicated smartphone app, aiming to enhance asthma management and adherence among young patients. 
• In November 2023, A Scottish start-up secured $2.5 million in funding to advance the development of a single-use dry powder inhaler. This innovative, cost-effective inhaler is constructed from cardboard and is designed to deliver a variety of dry powder medications. The start-up's approach reflects a growing trend in smart inhaler technology, focusing on improving accessibility and efficiency in respiratory care.

Key Takeaways from the Smart Inhalers Market Report Study

• Smart Inhalers Market size analysis for current Market size (2024), and Market forecast for 8 years (2025 to 2032)
• Top key product/services developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years
• Key Smart Inhalers Companies dominating the smart inhalers Market
• Various opportunities available for the other competitors in the smart inhalers Market space
• What are the top-performing segments in 2024? How these segments will perform in 2032?
• Which are the top-performing regions and countries in the current smart inhaler Market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for smart inhaler Market growth in the coming future?

Target Audience who can be benefited from the Smart Inhalers Market Report Study

• Smart inhaler Product providers
• Research organizations and consulting Smart Inhalers companies 
• Smart inhalers-related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and traders dealing in smart inhalers 
• Various end-users who want to know more about the smart inhalers Market and the latest developments in the smart inhalers Market

Stay Updated with us for Recent Articles @ Latest DelveInsight Blogs